EBMT-EHA CAR-T 2019 | CAR T-cell therapy for ALL
Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, discusses the accumulating body of evidence of CAR T-cell therapy bringing about high response rates, MRD negativity and cure for particular hematological malignancies. Prof. Mohty describes how the evidence is strongest in acute lymphoblastic leukemia (ALL), and this therapy is likely to become a mainstay of ALL treatment. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Prof. Mohty describes the main focus of side effects such as neurotoxicity and cytokine release syndrome (CRS), and the strategies used to implement CAR T-cell therapy within the clinical setting.
Get great new content delivered to your inboxSign up